Searched for
THE MYLAN PLANT IN INDIA
Mylan to invest $1 billion in India on capex in 6 yearsCurrently Mylan has 21 facilities and 15,000 employees working in India.- Add Pfizer, target price Rs 3,400: Centrum BrokingManagement is hopeful of achieving in-line or slightly better growth rate than the market.
- Culture of ‘bending rules’ in India challenges U.S. drug agencyThe US drug agency is bewildered with Indian pharma industry's culture of getting things done at all costs.
- Biocon, Mylan likely to appeal Delhi HC ruling on Roche's cancer drug trastuzumabThe order, which raised questions on the processes followed by the Indian drug controller in approving such drugs, could also affect the av...
- Mylan may buy contraceptive co Famy Care for Rs 3,000 croreMylan is said to have pipped private equity bids from Bain Capital and Advent to move closer to a deal. Hong Kong-based AIF Capital holds 1...
- Forcing out non-compete clause an irritant in pharma FDI: Rajiv Malik, president, MylanMylan, a US generic giant with $6.8 bn sales, has been aggressively investing in India, making a series of acquisitions in the last two yea...
- Strides to pay dividend of Rs 500 per share post Agila saleArcolab said it will pay a special dividend of Rs 500 per equity share following the completion of its sale of Agila Specialties division t...
- Agila, with first class people, is a very high-quality asset: Rajiv MalikMylan has completed the acquisition of Agila Specialties division from Strides Arcolab for a total value of $1.75 billion (about Rs10,800 c...
- Strides Arcolab plunges over 15% on completion of Agila saleThe pharmaceutical company said it has completed sale of its Agila Specialties Division to Mylan Inc for a total consideration of up to $1....
- Strides completes $1.75 billion sale of Agila Specialties to MylanStrides Arcolab said it has completed the sale of its Agila Specialties division to Mylan Inc for a total consideration of up to $1.75 bill...
- Ranbaxy hunts for FDA-okayed plants in IndiaThis move will ensure launch plans are not jeopardised following Mohali setback.
- USFDA warning letter to Agila not to affect acquisition: MylanMylan said the USFDA warning letter to Agila Specialties over violation of manufacturing norms in one of its plants will not affect the Rs ...
- We need to see more clarity in Indian policies: Rajiv Malik, Mylan IncFor example, when you see our growth for Matrix (it was acquired by Mylan in 2007), we have grown from 2,000 people to almost 10,000.
- DIPP halts Mylan’s takeover bid for AgilaThe Department of Industrial Policy and Promotion (DIPP) has put the brakes on US-based Mylan Inc’s plan to acquire Agila Specialties.
- US court rejects Mylan plea against RanbaxyA US court has dismissed Mylan’s attempt to prevent Ranbaxy from launching a low-cost version of Lipitor in Nov, expected to bring $550-600...
- Ranbaxy's Lipitor copy fate next weekA US court will decide next week if Ranbaxy can launch its low-priced version of the world's best selling drug Lipitor in the American mark...
- USFDA nod likely for Ranbaxy generic drugThe US drug regulator has opposed American firm Mylan Inc's request to strip Ranbaxy Laboratories of its six-month exclusive rights to sell...
- Newbridge may acquire Sigma Electric for $150mUS-BASED private equity player Newbridge is in talks to acquire Sigma Electric Manufacturing Corporation.
- Matrix deal to trigger M&As in pharma secGlobal majors, Teva, Watson, Barr and Activis are also eyeing mid-sized and large Indian cos.
- US pharma major Mylan buys Matrix LabsThe generic drugs major will acquir Hyderabad-based Matix Lab in a cash-and-stock deal worth Rs 3,424 cr.
Load More
